Affordable Access

deepdyve-link
Publisher Website

Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.

Authors
  • Ueno, Fumiaki1
  • Doi, Michio2
  • Kawai, Yumi2
  • Ukawa, Naoto2
  • Cammarota, Jordan3
  • Betts, Keith A3
  • 1 a Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital , Kanagawa , Japan. , (Japan)
  • 2 b AbbVie GK , Tokyo , Japan. , (Japan)
  • 3 c Analysis Group Inc , Los Angeles , CA , USA.
Type
Published Article
Journal
Journal of medical economics
Publication Date
Aug 13, 2019
Pages
1–6
Identifiers
DOI: 10.1080/13696998.2019.1642900
PMID: 31294641
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Aims: Adalimumab, infliximab, and ustekinumab have been approved for patients with moderate-to-severe Crohn's disease in Japan. This study compared the relative efficacy and cost-effectiveness of adalimumab, infliximab, and ustekinumab in patients with Crohn's disease based on data from randomized controlled trials. Methods: Data were extracted from four phase 3 clinical trials: CHARM, NCT00445432, ACCENT I, and IM-UNITI. A network meta-analysis (NMA) compared 1-year clinical remission rates in patients who responded to treatment during an induction phase. Remission was defined as a Crohn's Disease Activity Index score <150. The number needed to treat (NNT) was defined as the inverse of the risk reduction (compared with placebo) estimated from the NMA among initial responders. Cost per incremental remitter was calculated based on the projected per patient drug cost (2018 Japanese Yen [¥]) and the NNT. Results: Among initial responders, the remission rates were 45.2%, 31.9%, 27.4%, 24.1%, and 15.6% for adalimumab 40 mg every other week (EOW), infliximab 5 mg/kg every 8 weeks, ustekinumab 90 mg every 8 weeks, ustekinumab 90 mg every 12 weeks, and placebo, respectively. The NNT was the lowest for adalimumab 40 mg EOW. Compared with adalimumab, the incremental cost per remitter was numerically higher for infliximab (¥5,375,470) and statistically higher for ustekinumab 90 mg every 8 weeks and ustekinumab 90 mg every 12 weeks (¥42,788,597 and ¥41,495,543, respectively). Limitations: Indirect comparisons are limited by the availability of suitable clinical evidence and there may be residual heterogeneity that could not be adjusted for. Conclusion: Adalimumab was associated with a numerically lower cost per remitter compared with infliximab and a statistically lower cost per remitter compared with ustekinumab in patients with moderate-to-severe Crohn's disease in Japan.

Report this publication

Statistics

Seen <100 times